Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biphasic Insulin Regimens in Well-controlled T2DM
NCT04726657Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Jan 2016
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Aristotle University of Thessaloniki. Primary endpoint: Change in average blood glucose at 7 days. Started Jan 2016; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04726657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04726657.